<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990847</url>
  </required_header>
  <id_info>
    <org_study_id>002-IOA-0601</org_study_id>
    <nct_id>NCT00990847</nct_id>
  </id_info>
  <brief_title>Nebulized Procaterol Versus Nebule Salbutamol for the Treatment of Moderate Acute Asthma</brief_title>
  <official_title>The Efficacy of Nebulized Procaterol Versus Nebulized Salbutamol for the Treatment of Moderate Acute Asthma: a Randomized, Double-blind, Parallel Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Otsuka Indonesia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Otsuka Indonesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of nebule procaterol with
      nebule salbutamol in the treatment of moderate acute asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference 5% from baseline in peak expiratory flow rate (PEFR)</measure>
    <time_frame>3 times every 20 minutes (at 0, 20 and 40 minutes)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference 5% from baseline in asthma score</measure>
    <time_frame>3 times every 20 minutes (at 0, 20 and 40 minutes)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Moderate Acute Asthma</condition>
  <arm_group>
    <arm_group_label>Procaterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procaterol inhalation solution 50 micro g per 0.5 mL diluted in 2mL of NaCl 0.9%, so that the volume of the inhalation solution will be similar to that of the comparator drug. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salbultamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salbultamol inhalation solution for nebulization containing 2.5 mg in 2.5 mL aqueous solution. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procaterol, Salbultamol</intervention_name>
    <arm_group_label>Procaterol</arm_group_label>
    <arm_group_label>Salbultamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with moderate acute asthma according to Global Initiative for Asthma (GINA)
             1998 (Appendix 1). Patients with moderate acute asthma according to Modified Global
             Initiative for Asthma (GINA) 1998 (Patients with asthma score 5 - 11; PEFR â‰¤ 80%
             predicted)

          2. Patients of both gender aged 15 to 60 years

          3. Patients still have the ability to undergo examinations and give written informed
             consent

        Exclusion Criteria:

          1. Pregnant and lactating women

          2. Smokers

          3. Patients with heart disease, hyperthyroidism, diabetes mellitus, COPD or other chronic
             diseases

          4. Patients with signs of severe infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hadiarto Mangunnegoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pulmonology and Respiratory Medicine, Faculty of Medicine University of Indonesia/ Persahabatan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Indonesia/ Persahabatan Hospital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>October 6, 2009</last_update_submitted>
  <last_update_submitted_qc>October 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Albertus Widjaja/Medical Director</name_title>
    <organization>PT Otsuka Indonesia</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Procaterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

